# **1** Regional Variation in the Interpretation of Contact Precautions for Multidrug-

# 2 resistant Gram-negative bacteria: a cross-sectional survey

- 3 Anneloes van Veen<sup>1</sup>, Inge de Goeij<sup>1</sup>, Marjolein Damen<sup>2</sup>, Elisabeth G.W. Huijskens<sup>3</sup>, Sunita Paltansing<sup>4</sup>,
- 4 Michiel van Rijn<sup>5</sup>, Robbert G. Bentvelsen<sup>6,7</sup>, Jacobien Veenemans<sup>3,8</sup>, Michael van der Linden<sup>9</sup>, Margreet
- 5 C. Vos<sup>1</sup> and Juliëtte A. Severin<sup>1\*</sup> on behalf of the Infection Prevention and Antimicrobial Resistance
- 6 **Care Network South-western Netherlands.**
- 7 \* Corresponding author: j.severin@erasmusmc.nl
- 8
- 9 <sup>1</sup>Department of Medical Microbiology and Infectious Diseases, Erasmus MC University Medical Centre,
- 10 Rotterdam, The Netherlands.
- <sup>2</sup> Department of Medical Microbiology, Maasstad General Hospital, Rotterdam, The Netherlands.
- <sup>3</sup> Department of Medical Microbiology, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
- <sup>4</sup> Department of Medical Microbiology and Infection Prevention, Franciscus Gasthuis & Vlietland,
- 14 Rotterdam, The Netherlands.
- <sup>5</sup> Department of Medical Microbiology and Infectious Diseases, Ikazia Hospital, Rotterdam, The
- 16 Netherlands.
- <sup>6</sup> Department of Infection Prevention, Zorgsaam Hospital, Terneuzen, The Netherlands.
- <sup>7</sup> Microvida Laboratory for Microbiology, Amphia Hospital, Breda, The Netherlands.
- <sup>8</sup> Department of Infection Prevention, Admiraal de Ruyter Hospital, Goes, The Netherlands.
- <sup>9</sup> Department of Infection Prevention, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.

## 21 Summary

Background: Contact precautions (CP) are recommended when caring for patients with carbapenemaseproducing Enterobacterales (CPE), carbapenemase-producing *Pseudomonas aeruginosa* (CPPA), and

24 extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E).

25 Aim: Our aim was to determine the interpretation of CP and associated infection prevention and control

26 (IPC) measures in the non-ICU hospital setting for patients with CPE, CPPA or ESBL-E in 11 hospitals in the

27 Southwest of the Netherlands.

28 **Methods:** A cross-sectional survey was developed to collect information on all implemented IPC 29 measures, including use of personal protective equipment, IPC measures for visitors, cleaning and 30 disinfection, precautions during outpatient care and follow-up strategies. All eleven hospitals were invited 31 to participate between November 2020 and April 2021.

32 **Findings:** The survey was filled together with each hospital. All hospitals installed isolation precautions for 33 patients with CPE and CPPA during inpatient care and day admissions, whereas ten hospitals (90.9%) 34 applied isolation precautions for patients with ESBL-E. Gloves and gowns were always used during physical contact with the patient in isolation. Large variations were identified in IPC measures for visitors, cleaning 35 36 and disinfection products used, and precautions during outpatient care. Four hospitals (36.4%) actively 37 followed up on CPE or CPPA patients with the aim to declare them CPE- or CPPA-negative as timely as 38 possible, and two hospitals (20.0%) actively followed up on ESBL-E patients. 39 **Conclusion:** CP are interpreted differently between hospitals, leading to regional differences in IPC

40 measures applied in clinical settings. Harmonizing infection-control policies between the hospitals could

41 facilitate patient transfers and benefit collective efforts of preventing transmission of MDR-GNB.

42

Keywords: Carrier state, Enterobacteriaceae, Hospitals, Infection control, Multidrug resistance, Patient
 isolation, *Pseudomonas aeruginosa*

# 45 Introduction

Multidrug-resistant Gram-negative bacteria (MDR-GNB), including carbapenemase-producing Enterobacterales (CPE), carbapenemase-producing *Pseudomonas aeruginosa* (CPPA), and extendedspectrum β-lactamase-producing Enterobacterales (ESBL-E), are well-known causes of healthcareassociated infections. Infections with MDR-GNB are more difficult to treat compared to infections with susceptible Gram-negative bacteria, and are, therefore, associated with high morbidity and mortality [1-3]. In the Netherlands, CPE and CPPA are rare, with only sporadic outbreaks in Dutch hospitals [4]. ESBL-E are more often found, but prevalences are still low in comparison to other European countries [4-6].

53 Infection prevention and control (IPC) measures are essential to prevent or control nosocomial spread of 54 MDR-GNB. While there is in general international consensus on the application of contact precautions 55 (CP), in addition to standard precautions, when caring for patients colonized or infected with MDR-GNB, 56 international guidelines show some variation in their recommendations on related IPC measures, e.g., which personal protective equipment (PPE) healthcare workers (HCW) should use and when [7-14]. Also, 57 58 IPC measures needed in specific settings (e.g., during outpatient care or physiotherapy of a hospitalized 59 patient) and for different patient populations, are often not described, possibly due to a lack of studies in 60 these specific situations and, consequently, paucity of evidence [11, 15, 16].

61 Besides variation in or lack of recommendations on certain IPC measures in infection-control guidelines, 62 substantial variation in implemented IPC measures by healthcare facilities has been reported as well, both at the national and international level [11, 16-18]. Major differences were found, for example, in IPC 63 64 measures between hospitals in a small geographical area [19]. The Infection Prevention and Antimicrobial 65 Resistance (IP & AMR) Care Network South-western Netherlands is likewise a small geographical area, 66 with a relatively large number of hospitals [20]. Patients are frequently transferred between these 67 hospitals, which is a known risk factor for transmission of multidrug-resistant bacteria, and therefore 68 necessitates a collaborative approach with consensus on IPC measures to prevent or control spread [15, 69 21-23]. The aim of this study was to determine the interpretation of CP and associated IPC measures in 70 the non-ICU hospital setting for patients colonized or infected with CPE, CPPA or ESBL-E in the Southwest 71 of the Netherlands.

# 72 Methods

#### 73 Setting

This study was performed within the IP & AMR Care Network South-western Netherlands, which was established in 2015 as part of the Dutch AMR National Action Plan [24]. The eleven hospitals from the IP & AMR Care Network South-western Netherlands were invited to participate in this study, including one university hospital, six non-university teaching hospitals and four non-teaching hospitals (Supplementary Table A1).

## 79 Survey

We developed a cross-sectional survey to collect information on the IPC measures embedded in the hospitals' internal IPC policies for nine multidrug-resistant microorganisms (MRDO) [9]. Here, we only report on the IPC measures for CPE, CPPA, and ESBL-E. The survey focused on a variety of topics, including flagging of carriers in the electronic health record (EHR); isolation precautions during inpatient care, day admissions, and outpatient care; IPC measures for visitors of inpatients; terminal cleaning and disinfection; and follow-up of carriers and conditions for cessation of isolation measures. The majority of questions were multiple-choice, yet more detailed explanations could be given if necessary.

The survey was filled out together with one or multiple infection prevention practitioner(s) from each hospital during an online meeting between November 2020 and April 2021. In preparation of the meeting, the participants received the survey. After the meeting, the filled survey was sent to them by email to check whether the survey was filled out correctly. If necessary, answers could be added and modified after which the survey was sent back to the research team for analysis.

#### 92 Definitions

93 Supplementary Table A2 provides an overview of the IPC measures recommended by national and 94 international IPC guidelines for CPE, CPPA, and ESBL-E. The Dutch guidelines describe different types of 95 isolation, including strict isolation and contact isolation [25-27]. Currently, the Dutch MDRO guideline for 96 hospitals indicates that inpatients with CPE, CPPA, and ESBL-E should be cared for in contact isolation, and 97 specifically recommends using single-occupancy rooms when caring for patients with CPE [27]. Strict 98 isolation is only recommended for multidrug-resistant Acinetobacter species. Furthermore, the Dutch 99 MDRO guideline prescribes standard precautions, not targeted contact precautions, for patients visiting 100 the outpatient clinic. Cessation of isolation measures is not recommended during hospitalization,

- although it could be considered if isolation is a major burden for the patient's wellbeing and/or treatment.
- 102 In this case, two negative culture sets, with at least 24 hours in between, are required [27].

103 For the follow-up of MDR-GNB carriers, active, passive and no follow-up are distinguished. Active follow-

- 104 up is defined as requesting all MDR-GNB carriers to participate in taking screening cultures and actively
- 105 following them with the aim to declare patients MDR-GNB-negative as timely as possible. During passive
- 106 follow-up, however, patients only receive screening cultures on indication by the treating physician (e.g.,
- 107 when long-term isolation is detrimental to the patient's health and/or treatment) in order to safely
- 108 discontinue isolation measures following consecutive negative culture sets or are screened upon hospital
- admission. Hospitals not pursuing active or passive follow-up are categorized as no follow-up.

#### 110 Statistical analysis

- 111 IBM Statistical Package for the Social Sciences Solutions (SPSS) version 28 (IBM Corp., Armonk, New York,
- 112 USA) was used for the analyses. Missing data are reported as such. For descriptive purposes, frequencies
- and percentages were calculated, where appropriate.
- 114 **Results**

## 115 Carbapenemase-producing Enterobacterales & carbapenemase-producing Pseudomonas

116 aeruginosa

#### 117 Inpatient care and day admissions

The survey was filled together with each of the 11 hospitals. All hospitals flagged patients colonized or 118 119 infected with CPE and CPPA in their EHR. Infection-control policies for CPE and CPPA were in place in each 120 hospital, however, the number and strength of IPC measures applied varied (Table I). During inpatient 121 care and at day admissions, different types of isolation were applied: eight hospitals (72.7%) applied contact isolation, one hospital (9.1%) applied strict isolation, and two hospitals (18.2%) applied so-called 122 123 "contact-plus" isolation (Table I). "Contact-plus" isolation is not defined in any national or international 124 guideline. It is defined as isolation with measures that are in-between contact and strict isolation, as 125 defined in the Dutch guidelines, but it is applied differently in two hospitals [25-27]. At hospital 8, the 126 patient room's door had to remain closed during "contact-plus" isolation, but could be open during 127 contact isolation. "Contact-plus" isolation in hospital 1 differed from contact isolation in terms of the isolation measures required during outpatient care and the IPC measures for visitors. However, all 128 129 hospitals that installed contact isolation for CPE and CPPA carriers also applied stricter measures than the

Dutch contact isolation guideline prescribes (e.g., requiring HCWs to also wear a gown besides only gloves
or requiring the patient room's door to be closed), without defining it "contact-plus" isolation [26].

Most hospitals isolated CPE and CPPA patients during inpatient care in single-occupancy rooms with private bathrooms (n=10, 90.9%). While according to the Dutch guidelines an isolation room is only necessary for strict isolation, one hospital (9.1%) reported isolating CPE and CPPA carriers in isolation rooms, but still used the term contact isolation (Table I) [25]. Patients were preferably isolated in singleoccupancy rooms during day admissions (n=9, 81.8%), although shortage of such rooms could necessitate isolation in multiple-occupancy rooms (n=1, 9.1%).

Although in five hospitals (45.5%) the decision for HCW to put on PPE before entering a patient's room depended on whether contact with the patient was anticipated or not, in other hospitals HCW were required to wear PPE at all times when entering the patient's room (n=6, 54.5%). Overall, ten hospitals (90.9%) were more stringent compared to the Dutch contact isolation guideline, which requires HCW to

142 wear only gloves before having contact with the patient and/or the patient's environment [26].

## 143 Outpatient care

144 Four hospitals (36.4%) only used standard precautions when patients with CPE or CPPA visited the 145 outpatient clinic. Hospital 1 (9.1%) consistently applied "contact-plus" isolation during outpatient care (policy 1), while the other six hospitals (54.5%) followed different approaches to determine the type of 146 147 isolation (policy 2-5; Figure 1). These decisions depended on the type of patient visiting the outpatient 148 clinic, the type of procedure being performed, and/or on whether there would be physical contact with 149 the patient. In general, contact isolation was applied during invasive procedures and inpatients were 150 continued to be cared for in contact isolation when visiting the outpatient clinic. During contact isolation, 151 HCW were wearing a disposable gown and non-sterile gloves (Figure 1).

### 152 *IPC measures for visitors*

Visitors were requested to take precautions when visiting an inpatient with CPE or CPPA in all hospitals, ranging from hand disinfection (n=11, 100%) to, additionally, wearing a surgical mask, disposable gown, non-sterile gloves and hair cap as the most extensive IPC measures (n=1, 9.1%). In four hospitals (36.4%), visitors could temporarily leave a patient's room during their visit. Rooming-in was permitted in most hospitals (n=10, 90.9%), of which five hospitals (50.0%) allowed rooming-in visitors to temporarily leave the patient's room (Supplementary Table A3).

### 159 Cleaning & disinfection

160 Different cleaning and disinfection products were used (Supplementary Table A4). Most hospitals (n=9,

- 161 81.8%) replaced the separation curtains after cessation of isolation measures. One hospital (9.1%) also
- 162 changed the window curtains (Supplementary Table A4).
- 163 Follow-up of carriage and conditions for cessation of isolation measures

164 Various follow-up strategies were used (Table II). Active follow-up was done by four hospitals (36.4%), 165 wherein patients received a self-sampling set at home at different time intervals. Three hospitals (75.0%) 166 initiated active follow-up two months after a positive culture, yet one hospital (25.0%) started at least one 167 year after the last positive culture. The number of swabs needed to declare a patient CPE- or CPPA-168 negative varied between these four hospitals, from one negative culture to six consecutive negative 169 culture sets. Passive follow-up was performed in another four hospitals (36.4%). These hospitals all used 170 two consecutive negative cultures or culture sets for lifting isolation measures, but the initiation of follow-171 up varied from at least 48 hours after stopping relevant antibiotics to at least one year after the last 172 positive culture. Although negative cultures could lead to declaring a patient CPE- or CPPA-negative 173 followed by cessation of isolation measures, two hospitals (50.0%) continued to flag patient's EHR 174 indicating former CPE- or CPPA-carriage. Three hospitals (27.3%) did not follow up on CPE or CPPA carriers 175 and flagged patient's EHR indefinitely (Table II).

## 176 Extended-spectrum β-lactamase-producing Enterobacterales

## 177 Inpatient care and day admissions

178 Patients with ESBL-E were also flagged in each hospital's EHR. Hospital 2 (9.1%) did not apply isolation 179 precautions for ESBL-E carriers (Table I). Hospital 1 (9.1%) placed all patient groups with ESBL-E during 180 inpatient care in contact isolation, whereas isolation precautions varied for different patient groups during 181 day admissions. Inpatients undergoing a procedure at the day admissions centre remained in contact 182 isolation, whereas patients coming from home were cared for taking only standard precautions. Hospital 183 10 (9.1%) installed contact isolation for ESBL-E patients during inpatient care, yet "contact-plus" isolation 184 during day admissions. Lastly, eight hospitals (72.7%) applied contact isolation for all patients with ESBL-E during both inpatient care and day admissions. Although a single-occupancy room with private 185 186 bathroom remained preferable for inpatients with ESBL-E (n=8, 72.7%), several hospitals (n=6, 54.5%) also allowed these patients to stay in a multiple-occupancy room with or without dedicated bathroom due to 187 188 shortage of single-occupancy rooms (Table I).

189 The policy of PPE use by HCW was more constant over the hospitals. Approximately 70% of hospitals (n=8)

did not require HCW to wear any PPE upon room entrance when no patient contact was anticipated, while

ten hospitals (90.9%) required HCW to wear a gown and gloves when contact was anticipated (Table I).

### 192 Outpatient care

Six hospitals (54.5%) did not take isolation precautions for ESBL-E carriers during outpatient care (Figure 1). Hospital 1 and 11 (18.2%) only placed inpatients with an appointment at the outpatient department in contact isolation, whereas outpatients were cared for using only standard precautions (policy 4). The other three hospitals (27.3%) followed a similar two- or three category approach as used for patients with CPE and CPPA (policy 2, 3, and 5; Figure 1).

### 198 *IPC measures for visitors*

Ten hospitals (90.9%) requested visitors to apply IPC measures, of which all hospitals imposed hand disinfection. Hospital 10 (10.0%) asked visitors to additionally wear a gown and gloves. Rooming-in was allowed in most hospitals (n=9, 81.8%). Whether temporary room leave by visitors was allowed, varied depending on the underlying reason and whether it was a regular or rooming-in visitor (Supplementary Table A3).

#### 204 Cleaning & disinfection

A variety of cleaning and disinfection products was used after cessation of isolation measures (Supplementary Table A4). The separation curtains were replaced in seven hospitals (63.6%), while none of the hospitals changed the window curtains after cessation of isolation measures (Supplementary Table A4).

## 209 Follow-up of carriage and conditions for cessation of isolation measures

Four different strategies were used for follow-up of ESBL-E carriers (Table III). Two hospitals (18.2%) performed an active follow-up with varying duration and number of culture sets required. Whereas hospital 1 required two negative culture sets starting two months after the first positive culture with three days between culture sets, hospital 5 required one negative culture set at least one year after the last positive culture. Passive follow-up of ESBL-E carriers was performed by six hospitals (54.5%), with three hospitals (50.0%) screening on indication by the treating physician and three hospitals (50.0%) upon hospital admission. The former three hospitals all required two negative culture sets for the safe cessation

of isolation measures, although the timing of when to start culturing varied. Two hospitals (18.2%) did not
pursue any follow-up and unflagged the EHR automatically after one year.

## 219 **Discussion**

This study showed substantial variation in the interpretation of CP and associated IPC measures for patients with CPE, CPPA and ESBL-E in the non-ICU setting in hospitals in the Southwest of the Netherlands. Unsurprisingly, most variation was observed in the IPC measures applied in clinical settings, which are not well-defined in national and/or international guidelines.

224 The hospitals had different interpretations of CP, which is particularly highlighted by the introduction of 225 a new type of isolation, "contact-plus" isolation, and the variation observed in associated IPC measures 226 outlined in each hospital's internal IPC policies. Similar to previous findings, most and most stringent IPC 227 measures are applied for patients with CPE and CPPA compared to ESBL-E [11, 18, 19]. Variability in the 228 type of room used, types of PPE used by HCW, and environmental cleaning regimens were demonstrated 229 between hospitals for each MDR-GNB, which also confirms findings from previous studies [11, 16-19]. 230 Moreover, considerable variation was observed in the IPC measures taken during outpatient care, with 231 some hospitals installing no isolation precautions and other hospitals following a stepwise approach to 232 determine which type of isolation, if any, was required for each patient.

233 Evidence-based recommendations on follow-up of MDR-GNB carriers and conditions for safe cessation of 234 isolation measures are unavailable in international infection-control guidelines, possibly due to scarcity of 235 data on the duration of colonization and the occurrence of relapse of recolonization. The Dutch MDRO guideline also offers limited guidance [27]. This is reflected in the large variety of follow-up strategies 236 237 within our region, which varied from actively reaching out to patients with the aim to declare patients 238 MDR-GNB-negative as timely as possible to no follow-up and flagging the EHR indefinitely. [28-31]. A 239 direct comparison between different follow-up strategies in terms of duration and number of culture sets 240 could be of added value in efforts to harmonize follow-up strategies.

In general, variation in implemented IPC measures on international, national, and regional levels, seems to depend on the availability of IPC guidelines for MDR-GNB, the evidence-base and level of detail of the IPC measures recommended in these guidelines, local context and epidemiology, and organizational resources (e.g., number and availability of single-occupancy rooms and personnel) [16-19]. National and international guidelines are available, yet, in practice, individual hospitals seem to apply the recommended measures quite differently. For example, hospital 2 does not apply CP for ESBL-E carriers,

247 which is not in line with both the Dutch and European Society of Clinical Microbiology and Infectious 248 Diseases (ESCMID) guidelines (with the exception of Escherichia coli), and the active follow-up performed 249 by several hospitals is not described in any national or international guideline whatsoever. Some regional 250 differences can be explained by the patient populations served by the hospitals. Hospital 1 and 4, for 251 example, provide tertiary care for critically-ill patients, resulting in a more intensive follow-up to prevent 252 nosocomial transmissions among their vulnerable patients. The smaller hospitals may have less resources 253 available and are, therefore, restricted in pursuing such intensive efforts. Also, hospital 1 and 4 have 100% 254 adult single-occupancy rooms available, whereas the other, especially smaller, hospitals may need to 255 deviate from their own and other hospitals' policies, by occasionally placing MDR-GNB-positive patients 256 in multiple-occupancy rooms due to shortage of single-occupancy rooms.

257 The observed regional variety shows the need to harmonize IPC measures, since one hospital's actions (or 258 non-actions) may impact other hospitals in the region that share patients [32]. Harmonizing measures, 259 including conditions for cessation of isolation measures, may have a positive effect on MDR-GNB 260 prevalence, may facilitate inter-hospital communication, provides HCWs clarity during patient transfers, 261 and can lead to guicker and more effective actions to prevent or stop MDR-GNB spread between hospitals 262 [19, 33, 34]. Also, it may cause more understanding and acceptance of IPC measures by patients (and their 263 visitors) when they receive care in different hospitals, which may cause higher compliance with the 264 installed measures. Research has shown that enhanced coordination in infection prevention within a 265 region leads to greater synergistic effects, benefiting both individual hospitals and the entire region [32, 266 35-37].

However, which particular IPC measures are most effective and should thus be prioritised in specific settings remains somewhat unclear. Studies on the effectiveness of CP often lack information on the details of CP applied in specific settings, complicating the interpretation of their results [38, 39]. For example, whether a dedicated bathroom was used and whether terminal cleaning and disinfection of that bathroom was performed after cessation of isolation measures is frequently not described, while its importance is increasingly recognized. Therefore, authors should provide more details about which specific IPC measures are considered part of CP in their studies.

### 274 Strengths and limitations

A strength of this study is its multicentre design, with all hospitals in our region participating. This allowed
 for a comprehensive overview of the IPC measures applied in the hospitals. Additionally, the

extensiveness of the survey enabled us to uncover and compare details of IPC components associated with CP and isolation. A limitation of this study is that we did not ask the hospitals about the underlying reasons for choices made regarding their IPC policies. Future efforts should be aimed at harmonizing

regional IPC policies, followed by measurement of each hospital's compliance with these policies.

# 281 **Conclusions**

Hospitals in the Southwest of the Netherlands reported considerable variation in the interpretation of CP and associated IPC measures when caring for patients with CPE, CPPA and ESBL-E. Heterogeneity in policies appeared most prevalent for isolation precautions during outpatient care and follow-up of carriers, which are not (well-)defined in national and/or international guidelines. Future research should explore the setting-specific reasons and risks related to these differences in IPC measures. Harmonizing infection-control policies between hospitals could facilitate patient transfers and benefit collective efforts of preventing MDR-GNB transmission.

289

# 290 Acknowledgements

The authors would like to acknowledge the contributions of Janet Vos, former network manager of the IP & AMR Care Network South-western Netherlands, and all infection prevention practitioners from participating hospitals.

## 294 Conflict of interest

295 The authors declare no conflict of interest.

# 296 Source of funding

- 297 The project was carried out within the Infection Prevention and Antimicrobial Resistance Care Network
- 298 South-western Netherlands that receives funding from the Ministry of Health, Welfare and Sports.

# 299 References

- 300 [1] Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a
- 301 systematic analysis. Lancet 2022;399(10325):629-55.
- 302 [2] Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate
- 303 for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol
- 304 2009;30(10):972-6.
- 305 [3] Saharman YR, Pelegrin AC, Karuniawati A, Sedono R, Aditianingsih D, Goessens WHF, et al.
- 306 Epidemiology and characterisation of carbapenem-non-susceptible Pseudomonas aeruginosa in a large
- intensive care unit in Jakarta, Indonesia. Int J Antimicrob Agents 2019;54(5):655-60.
- 308 [4] Nethmap/MARAN. NethMap 2021: Consumption of antimicrobial agents and antimicrobial
- resistance among medically important bacteria in the Netherlands. 2021.
- 310 [5] European Centre for Disease Prevention and Control. European Antimicrobial Resistance
- 311 Surveillance Network (EARS-Net), https://www.ecdc.europa.eu/en/about-us/networks/disease-
- 312 <u>networks-and-laboratory-networks/ears-net-data</u>; 2021 [accessed April 4 2023.].
- 313 [6] van der Schoor AS, Severin JA, Klaassen CHW, van den Akker JPC, Bruno MJ, Hendriks JM, et al.
- 314 Universal screening or a universal risk assessment combined with risk-based screening for multidrug-
- resistant microorganisms upon admission: Comparing strategies. PLoS One 2023;18(7):e0289163.
- 316 [7] Tacconelli E, Cataldo MA, Dancer SJ, De Angelis G, Falcone M, Frank U, et al. ESCMID guidelines
- 317 for the management of the infection control measures to reduce transmission of multidrug-resistant
- 318 Gram-negative bacteria in hospitalized patients. Clin Microbiol Infect 2014;20 Suppl 1:1-55.
- 319 [8] Siegel JD, Rhinehart E, Jackson M, Chiarello L, Health Care Infection Control Practices Advisory C.
- 320 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care
- 321 Settings. Am J Infect Control 2007;35(10 Suppl 2):S65-164.
- Kluytmans-Vandenbergh MF, Kluytmans JA, Voss A. Dutch guideline for preventing nosocomial
   transmission of highly resistant microorganisms (HRMO). Infection 2005;33(5-6):309-13.
- 324 [10] Magiorakos AP, Burns K, Rodríguez Baño J, Borg M, Daikos G, Dumpis U, et al. Infection
- 325 prevention and control measures and tools for the prevention of entry of carbapenem-resistant
- 326 Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention
- and Control. Antimicrob Resist Infect Control 2017;6:113.

- 328 [11] Lynch BL, Schaffer K. Can guidelines for the control of multi-drug-resistant Gram-negative
- 329 organisms be put into practice? A national survey of guideline compliance and comparison of available
- 330 guidelines. J Hosp Infect 2019;102(1):1-7.
- 331 [12] HSE Antimicrobial Resistance and Infection Control. Management and Control of
- 332 Carbapenemase Producing Enterobacterales (CPE) in all Healthcare Settings. Dublin: HSE-AMRIC; ;
- 333 December 2022.
- 334 [13] Otter JA, Mutters NT, Tacconelli E, Gikas A, Holmes AH. Controversies in guidelines for the
- 335 control of multidrug-resistant Gram-negative bacteria in EU countries. Clin Microbiol Infect
- 336 2015;21(12):1057-66.
- 337 [14] Centers for Disease Control. Facility guidance for control of carbapenem-resistant
- 338 Enterobacteriaceae (CRE): November 2015 update CRE Toolkit. 2015.
- 339 [15] European Centre for Disease Prevention and Control. Risk assessment on the spread of
- 340 carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare
- 341 facilities, with special emphasis on cross-border transfer. 2011.
- 342 [16] Tacconelli E, Buhl M, Humphreys H, Malek V, Presterl E, Rodriguez-Baño J, et al. Analysis of the
- challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in
  Europe. BMJ Open 2019;9(5):e027683.
- 345 [17] van Dijk MD, Voor In 't Holt AF, Alp E, Hell M, Petrosillo N, Presterl E, et al. Infection prevention
   346 and control policies in hospitals and prevalence of highly resistant microorganisms: an international
- 347 comparative study. Antimicrob Resist Infect Control 2022;11(1):152.
- 348 [18] Gysin DV, Cookson B, Saenz H, Dettenkofer M, Widmer AF, Infections ESGfN. Variability in
- 349 contact precautions to control the nosocomial spread of multi-drug resistant organisms in the endemic
- 350 setting: a multinational cross-sectional survey. Antimicrob Resist Infect Control 2018;7:81.
- 351 [19] Tschudin-Sutter S, Lavigne T, Grundmann H, Rauch J, Eichel VM, Deboscker S, et al. Differences
- in infection control and diagnostic measures for multidrug-resistant organisms in the tristate area of
- 353 France, Germany and Switzerland in 2019 survey results from the RH(E)IN-CARE network. Swiss Med
- 354 Wkly 2021;151:w20454.
- 355 [20] Infectiepreventie & Antibioticaresistentie Zorgnetwerk Zuidwest-Nederland. Aanpak
- 356 antibioticaresistentie en infectiepreventie Zuidwest-Nederland, <u>https://abrzorgnetwerkzwn.nl/;</u>
- 357 [accessed Feb 13 2024].
- 358 [21] Rogers BA, Aminzadeh Z, Hayashi Y, Paterson DL. Country-to-country transfer of patients and
- the risk of multi-resistant bacterial infection. Clin Infect Dis 2011;53(1):49-56.

360 [22] Donker T, Wallinga J, Grundmann H. Patient referral patterns and the spread of hospital-

acquired infections through national health care networks. PLoS Comput Biol 2010;6(3):e1000715.

362 [23] Ciccolini M, Donker T, Köck R, Mielke M, Hendrix R, Jurke A, et al. Infection prevention in a

363 connected world: the case for a regional approach. Int J Med Microbiol 2013;303(6-7):380-7.

364 [24] Tweede Kamer der Staten-Generaal. Kamerbrief 32620, nr. 159. 2015.

365 [25] Dutch Working Party on Infection Prevention (WIP). Strikte isolatie. 2006.

366 [26] Dutch Working Party on Infection Prevention (WIP). Contactisolatie. 2006.

367 [27] Dutch Working Party on Infection Prevention (WIP). Bijzonder resistente micro-organismen368 (BRMO). 2012.

369 [28] van Dijk MD, Voor In 't Holt AF, Polinder S, Severin JA, Vos MC. The daily direct costs of isolating

370 patients identified with highly resistant micro-organisms in a non-outbreak setting. J Hosp Infect

371 2021;109:88-95.

372 [29] Roth JA, Hornung-Winter C, Radicke I, Hug BL, Biedert M, Abshagen C, et al. Direct Costs of a

373Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital. Infect Control Hosp

374 Epidemiol 2018;39(1):101-3.

375 [30] Mehrotra P, Croft L, Day HR, Perencevich EN, Pineles L, Harris AD, et al. Effects of contact

376 precautions on patient perception of care and satisfaction: a prospective cohort study. Infect Control

377 Hosp Epidemiol 2013;34(10):1087-93.

378 [31] Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. Jama
379 2003;290(14):1899-905.

Lee BY, Yilmaz SL, Wong KF, Bartsch SM, Eubank S, Song Y, et al. Modeling the regional spread
 and control of vancomycin-resistant enterococci. Am J Infect Control 2013;41(8):668-73.

382 [33] Jurke A, Daniels-Haardt I, Silvis W, Berends MS, Glasner C, Becker K, et al. Changing

383 epidemiology of meticillin-resistant *Staphylococcus aureus* in 42 hospitals in the Dutch-German border

region, 2012 to 2016: results of the search-and-follow-policy. Euro Surveill 2019;24(15).

385 [34] Jurke A, Kock R, Becker K, Thole S, Hendrix R, Rossen J, et al. Reduction of the nosocomial

386 meticillin-resistant *Staphylococcus aureus* incidence density by a region-wide search and follow-strategy

in forty German hospitals of the EUREGIO, 2009 to 2011. Euro Surveill 2013;18(36):pii=20579.

388 [35] Bartsch SM, Wong KF, Mueller LE, Gussin GM, McKinnell JA, Tjoa T, et al. Modeling Interventions

to Reduce the Spread of Multidrug-Resistant Organisms Between Health Care Facilities in a Region.

390 JAMA Netw Open 2021;4(8):e2119212.

391 [36] Lee BY, Bartsch SM, Wong KF, McKinnell JA, Slayton RB, Miller LG, et al. The Potential Trajectory 392 of Carbapenem-Resistant Enterobacteriaceae, an Emerging Threat to Health-Care Facilities, and the 393 Impact of the Centers for Disease Control and Prevention Toolkit. Am J Epidemiol 2016;183(5):471-9. 394 [37] Lee BY, Bartsch SM, Wong KF, Yilmaz SL, Avery TR, Singh A, et al. Simulation shows hospitals that 395 cooperate on infection control obtain better results than hospitals acting alone. Health Aff (Millwood) 396 2012;31(10):2295-303. Maechler F, Schwab F, Hansen S, Fankhauser C, Harbarth S, Huttner BD, et al. Contact isolation 397 [38] 398 versus standard precautions to decrease acquisition of extended-spectrum β-lactamase-producing 399 Enterobacterales in non-critical care wards: a cluster-randomised crossover trial. Lancet Infect Dis 400 2020;20(5):575-84.

- 401 [39] Kluytmans-van den Bergh MFQ, Bruijning-Verhagen PCJ, Vandenbroucke-Grauls C, de Brauwer E,
- 402 Buiting AGM, Diederen BM, et al. Contact precautions in single-bed or multiple-bed rooms for patients
- 403 with extended-spectrum β-lactamase-producing Enterobacteriaceae in Dutch hospitals: a cluster-
- 404 randomised, crossover, non-inferiority study. Lancet Infect Dis 2019;19(10):1069-79.

405

Transmission-based precautions	CPE	СРРА	ESBL-E
Isolation precautions during inpatient care			
Yes	11 (100)	11 (100)	10 (90.9)
No	0 (0.0)	0 (0.0)	1 (9.1)
Type of isolation			
Strict isolation	1 (9.1)	1 (9.1)	0 (0.0)
Contact-plus isolation	2 (18.2)	2 (18.2)	0 (0.0)
Contact isolation	8 (72.7)	8 (72.7)	10 (90.9)
No isolation	0 (0.0)	0 (0.0)	1 (9.1)
IPC measures during inpatient care			
Type of room <sup>1,2</sup>			
Isolation room with anteroom and private bathroom	2 (18.2)	2 (18.2)	0 (0.0)
Single-patient room with private bathroom	10 (90.9)	10 (90.9)	8 (72.7)
Single-patient room with shared bathroom	1 (9.1)	1 (9.1)	1 (9.1)
Multiple-occupancy room with dedicated bathroom	1 (9.1)	1 (9.1)	3 (27.3)
Multiple-occupancy room with shared bathroom	0 (0.0)	0 (0.0)	3 (27.3)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
HCWs PPE: entering the patient room without patient			
contact <sup>3</sup>			
No PPE	5 (45.5)	5 (45.5)	8 (72.7)
Non-sterile gloves	1 (9.1)	1 (9.1)	1 (9.1)
Disposable gown and non-sterile gloves	4 (36.4)	4 (36.4)	1 (9.1)
Surgical mask type IIR, disposable gown, non-sterile			
gloves, and hair cap	1 (9.1)	1 (9.1)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
HCWs PPE: entering the patient room with patient			
contact <sup>3</sup>			
Gown and gloves	10 (90.9)	10 (90.9)	10 (90.9)
IIR surgical mask, gown, gloves, and hair cap	1 (9.1)	1 (9.1)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)

406 **Table I** Transmission-based precautions during inpatient care and day admissions (n=11 hospitals).

Yes	6 (54.5)	7 (63.6)	9 (81.8)
No	5 (45.5)	4 (36.4)	1 (9.1)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
Physiotherapy is allowed in public gym			
Yes	5 (45.5)	5 (45.5)	7 (63.6)
No	4 (36.4)	4 (36.4)	1 (9.1)
Not applicable	2 (18.2)	2 (18.2)	3 (27.3)
Physiotherapy in corridors and stairwells is allowed			
Yes	8 (72.7)	8 (72.7)	10 (90.9)
No	3 (27.3)	3 (27.3)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
Physiotherapist with PPE	6 (75.0)	6 (75.0)	6 (60.0)
Patient with PPE	1 (12.5)	1 (12.5)	1 (10.0)
No PPE for physiotherapist or patient	1 (12.5)	1 (12.5)	2 (20.0) <sup>4</sup>
Mandatory to report physiotherapy to infection			
prevention team			
Yes	5 (55.6)	5 (55.6)	5 (45.5)
No	4 (36.4)	4 (36.4)	5 (45.5)
Not applicable	2 (18.2)	2 (18.2)	1 (9.1)
Isolation precautions during day admissions			
Yes	11 (100)	11 (100)	9 (81.8)
Only for a specific patient group	0 (0.0)	0 (0.0)	1 (9.1)
No	0 (0.0)	0 (0.0)	1 (9.1)
Type of isolation			
Strict isolation	1 (9.1)	1 (9.1)	0 (0.0)
Contact-plus isolation	2 (18.2)	2 (18.2)	1 (9.1)
Contact isolation	8 (72.7)	8 (72.7)	9 (81.8)
No isolation	0 (0.0)	0 (0.0)	1 (9.1)
IPC measures during day admissions			
Type of room <sup>5</sup>			
Single-patient room	9 (81.8)	9 (81.8)	5 (45.5)
Multiple-occupancy room	1 (9.1)	1 (9.1)	4 (36.4)

Not applicable	1 (9.1)	1 (9.1)	2 (18.2)
HCW PPE in treatment room <sup>3</sup>			
No PPE	0 (0.0)	0 (0.0)	0 (0.0)
Non-sterile gloves	0 (0.0)	0 (0.0)	0 (0.0)
Disposable gown and non-sterile gloves	10 (90.9)	10 (90.9)	10 (90.9)
Surgical mask type IIR, disposable gown, non-sterile			
gloves, and hair cap	1 (9.1)	1 (9.1)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
Allowed to be accompanied by a visitor			
Yes	11 (100)	11 (100)	10 (90.9)
No	0 (0.0)	0 (0.0)	0 (0.0)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)
Visitor also placed in isolation			
Yes	6 (54.5)	6 (54.5)	4 (36.4)
No	5 (45.5)	5 (45.5)	6 (54.5)
Not applicable	0 (0.0)	0 (0.0)	1 (9.1)

407 Data are N (%). CPPA carbapenemase-producing Pseudomonas aeruginosa, CPE carbapenemase-

408 producing Enterobacterales, *ESBL-E* extended-spectrum β-lactamase-producing Enterobacterales, *HCW* 

409 healthcare worker, *IPC* infection prevention and control, *PPE* personal protective equipment.

410 <sup>1</sup> Multiple answers per hospital possible.

411 <sup>2</sup> An isolation room is defined as a single-occupancy room with anteroom and pressure difference. A

412 multiple-occupancy patient room is considered to be a room in which other bed(s) may be occupied


413 both by carriers of the same or different resistant bacteria, and non-carriers.


<sup>3</sup> A disposable gown was defined as a long-sleeved gown in 10 out of 11 hospitals. Hospital 9 used a

415 long-sleeved gown when caring for patients in strict isolation, which this hospital applied to patients

416 with CPE or CPPA, and an apron when caring for patients in contact isolation, which this hospital applied

- 417 to patients with ESBL-E.
- 418 <sup>4</sup>One answer is missing.
- <sup>5</sup> Procedures taking place in the day admissions centre are e.g., minor surgical procedures,
- 420 haemodialysis, hemapheresis, etc. The answer is not applicable when a patient directly goes home after
- 421 the procedure has been performed in an operating room.





- 424 Data are N (%). CPE carbapenemase-producing Enterobacterales, CPPA carbapenemase-producing Pseudomonas aeruginosa, ESBL-E extended-
- 425 spectrum β-lactamase-producing Enterobacterales, HCW healthcare workers, IPC infection prevention and control, N/A not applicable, PPE
- 426 personal protective equipment.

423

427 \*For policy 1, one hospital also includes patients with skin conditions and open wounds in category 1 'Outpatients, invasive procedure'.

	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital
	1	4	5	10	2	3	6	11	7	8	9
Contraindications	Yes,	Yes,	None	Yes,	Yes,	Yes,	Yes,	Yes,	N/A	N/A	N/A
for initiation of	antibiotic	antibiotic		antibiotic	antibiotic	antibiotic	antibiotic	antibiotic			
active follow-up or	use and	use		use	use and	use;	use	use,			
culturing	hospital				hospital	hospital		drains,			
	admission				admission	admission		and			
						only for		wounds			
						СРРА					
Active, passive or	Active	Active	Active	Active	Passive	Passive	Passive	Passive	No	No	No
no follow-up									follow-	follow-	follow-
									up	up	up
Method of	Self-	Letter,	Self-	Self-	N/A	N/A	N/A	N/A	N/A	N/A	N/A
approaching	sampling set	followed	sampling	sampling							
patients	by regular	by self-	set by	set by							
	mail	sampling	regular	regular							
		set by	mail	mail							
		regular									
		mail									
Number of follow-	6 sets of 2	5 sets of 1	1 set of 2	5 sets of	2 sets of 3	2 sets of 1	2 sets of 1	2 sets of	N/A	N/A	N/A
up swabs	swabs	swab	swabs	1 swab	swabs	swab	swab	1 swab			

**Table II** Follow-up and conditions for cessation of isolation measures for patients with CPE and CPPA (n=11 hospitals).

Body sites	Throat,	Rectum,	Throat	Rectum	Throat,	Rectum	Rectum	Rectum;	N/A	N/A	N/A
sampled	rectum,	urine only	and	(or	nose,			wounds			
	wounds (if	in case of	rectum	faeces)	rectum,			(if			
	present),	UTI or			wounds (if			present)			
	urine and	catheter			present),			for CPE			
	sputum for				urine (if						
	CPE (if				catheter),						
	applicable)				sputum (if						
					productive						
					cough,						
					intubation						
					or						
					tracheo-						
					stomy)						
Start active follow-	Two months	Two	At least	Two	48 hours	Two	At least 48	At least	N/A	N/A	N/A
up or culturing	after first	months	one year	months	after	months	hours after	one year			
	positive	after the	after the	after the	stopping	after the	stopping	after the			
	culture and	last	last	last	antibiotics	last	antibiotics	last			
	without	positive	positive	positive		positive		positive			
	contra-	culture	culture	culture		culture		culture			
	indications										

Intervals	Every two	Every two	N/A	Every two	At least 24	Two days	24 hours	At least	N/A	N/A	N/A
	months	months		months	hours			24 hours			
Unflagging	After 6	After 5	After 1	After 5	After 2	After 2	Never <sup>2</sup>	After 2	Never	Never	Never
patient's EHR	negative	negative	year with	negative	negative	negative		negative			
	culture sets	culture	1 negative	cultures	culture	cultures		culture			
		sets within	culture		sets <sup>1</sup>			sets			
		1 year	set								

429 *CPPA* carbapenemase-producing *Pseudomonas aeruginosa*, CPE carbapenemase-producing Enterobacterales, *N/A* not applicable, *UTI* urinary

430 tract infection.

431 Blue columns indicate passive follow-up of carriers. Number and frequency of cultures described in the blue columns represents the cultures

432 needed for safe cessation of isolation measures during hospitalization.

<sup>1</sup> Electronic label is changed to 'Multidrug-resistant microorganism in the past', which means that patients are screened during each subsequent
 hospitalization.

435 <sup>2</sup> Electronic label remains at all times, however, isolation measures are scaled down in case screening cultures are negative after one year.

436 Patients are screened during each subsequent hospitalization.

437	Table III Follow-up and conditions for cessation of isolation measures for patients with ESBL-E (n=11 hospitals)	.).
-----	--	-----

	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital	Hospital
	1	5	3	6	11	8	9	4	10	7	2
Contraindications for	Yes,	None	Yes,	Yes,	Yes,	Yes,	Yes,	Yes,	N/A	N/A	N/A
initiation of active	antibiotic		antibiotic	antibiotic	antibiotic	antibiotic	antibiotic	antibiotic			
follow-up or culturing	use and		use	use	use,	use	use, hospital	use			
	hospital				drains,		admission <sup>1</sup> ,				
	admission				and		catheter,				
					wounds		drains,				
							wounds				
Active, passive or no	Active	Active	Passive	Passive	Passive	Passive	Passive	Passive	No	No	N/A
follow-up									follow-	follow-	
									up	up	
Method of	Self-	Self-	N/A	N/A	N/A	On	On	On	N/A	N/A	N/A
approaching patients	sampling	sampling				admission	admission	admission			
	set by	set by									
	regular	regular									
	mail	mail									
Number of follow-up	2 sets of 2	1 set of 2	2 sets of	2 sets of 1	2 sets of	1 set of 1	1 set of 1	1 set of 1	N/A	N/A	N/A
swabs	swabs	swabs	1 swab	swab	1 swab	swab	swab	swab			

Body sites sampled	Throat,	Throat	Rectum	Rectum	Rectum;	Rectum;	Rectum	Rectum;	N/A	N/A	N/A
	rectum,	and			wounds	wounds (if	(throat in	urine (if			
	wounds (if	rectum			(if	present);	neonates);	applicable)			
	present),				present)	urine (if	wounds (if				
	urine (if					catheter);	present);				
	applicable)					sputum (if	urine (if				
						productive	catheter);				
						cough)	sputum (if				
							productive				
							cough or				
							intubation).				
Start active follow-up	Two	At least	Two	At least 48	At least	One year	At least one	N/A	N/A	N/A	N/A
Start active follow-up or culturing	Two months	At least one year	Two months	At least 48 hours after			At least one year after	N/A	N/A	N/A	N/A
				hours after				N/A	N/A	N/A	N/A
	months	one year	months	hours after	one year	after first	year after	N/A	N/A	N/A	N/A
	months after first	one year after the	months after first	hours after stopping	one year after the	after first positive	year after first positive	N/A	N/A	N/A	N/A
	months after first positive	one year after the last	months after first positive	hours after stopping	one year after the last	after first positive	year after first positive	N/A	N/A	N/A	N/A
	months after first positive culture	one year after the last positive	months after first positive	hours after stopping	one year after the last positive	after first positive	year after first positive	N/A	N/A	N/A	N/A
	months after first positive culture and	one year after the last positive	months after first positive	hours after stopping	one year after the last positive	after first positive	year after first positive	N/A	N/A	N/A	N/A
	months after first positive culture and without	one year after the last positive	months after first positive	hours after stopping	one year after the last positive	after first positive	year after first positive	N/A	N/A	N/A	N/A
	months after first positive culture and without contra-	one year after the last positive culture	months after first positive	hours after stopping antibiotics	one year after the last positive	after first positive	year after first positive	N/A N/A	N/A N/A	N/A N/A	N/A N/A
or culturing	months after first positive culture and without contra- indications	one year after the last positive culture	months after first positive culture	hours after stopping antibiotics	one year after the last positive culture	after first positive culture	year after first positive culture				

	culture		culture								
	sets		sets								
Unflagging patient's	After 2	After 1	After 2	Never <sup>2</sup>	After 2	After 1	After at	After 1	After 1	After 1	After 1
EHR	negative	year with	negative		negative	year with	least one	year	year	year	year
	culture	1	culture		culture	1 negative	year with 1				
	sets	negative	sets		sets	culture set	negative				
		culture					culture set				
		set									

438 *ESBL-E* extended-spectrum  $\beta$ -lactamase-producing Enterobacterales, *N/A* not applicable.

439 Blue columns indicate passive follow-up of carriers. Number and frequency of cultures described in the blue columns represents the cultures

440 needed for safe cessation of isolation measures during hospitalization.

<sup>1</sup> Only during the initial clinical admission (i.e., when ESBL-E is first detected in a patient), hospital admission is considered a contraindication for

442 culturing in order to declare the patient ESBL-E negative.

<sup>2</sup> Electronic label remains at all times, however, isolation measures are scaled down in case screening cultures are negative after one year.

444 Patients are screened during each subsequent hospitalization.

# 445 Supplementary material

- 446 Supplementary Table A1: Characteristics of the eleven hospitals from the Southwest region of the
- 447 Netherlands.
- 448 Supplementary Table A2: IPC measures recommended by the Dutch, ESCMID and ECDC guidelines.
- 449 Supplementary Table A3: IPC measures for visitors of inpatients (n=11 hospitals).
- 450 Supplementary Table A4: Cleaning and disinfection after discharge of the patient (n=11 hospitals).